News
New First-Line Treatment Option for BRAF V600E–Mutant Metastatic Colorectal Cancer
January 2026 Some individuals with metastatic colorectal cancer have a specific genetic change called BRAF V600E. This mutation is linked to faster-growing...
Impact of physical activity on fatigue and quality of life in non-metastatic colorectal cancer
January 2026 Results from the International ColoCare Study were presented at this year's ASCO GI Symposium and found that greater levels of...
Nonoperative Management After Total Neoadjuvant Therapy in Rectal Cancer
A recent Italian phase II clinical trial (NO-CUT), published in The Lancet Oncology, evaluated whether some patients with stage II–III rectal cancer can...
The ATOMIC study: atezolizumab plus FOLFOX chemotherapy significantly improves disease-free survival and reduces the risk of recurrence in stage III colon cancer
A new study - the ATOMIC trial - has found that adding the immunotherapy atezolizumab to standard chemotherapy (FOLFOX) significantly improves outcomes for people with...
Ultraprocessed Food Consumption and Risk of Early-Onset Colorectal Cancer Precursors Among Women
November 2025 A new study published in JAMA Oncology found that women who eat more ultraprocessed foods (UPFs) such as packaged snacks, sugary drinks, and...
Microplastics in the Gut Linked to Colorectal Cancer-Like Patterns
November 2025 New research from the microONE project (CBmed GmbH, Austria) suggests that microplastics may impact gut health by altering...
Get social
New First-Line Treatment Option for BRAF V600E–Mutant Metastatic Colorectal Cancer
January 2026 Some individuals with metastatic colorectal cancer have a specific genetic change called BRAF V600E. This mutation is linked to faster-growing...
Impact of physical activity on fatigue and quality of life in non-metastatic colorectal cancer
January 2026 Results from the International ColoCare Study were presented at this year's ASCO GI Symposium and found that greater levels of...
Nonoperative Management After Total Neoadjuvant Therapy in Rectal Cancer
A recent Italian phase II clinical trial (NO-CUT), published in The Lancet Oncology, evaluated whether some patients with stage II–III rectal cancer can...
The ATOMIC study: atezolizumab plus FOLFOX chemotherapy significantly improves disease-free survival and reduces the risk of recurrence in stage III colon cancer
A new study - the ATOMIC trial - has found that adding the immunotherapy atezolizumab to standard chemotherapy (FOLFOX) significantly improves outcomes for people with...
Ultraprocessed Food Consumption and Risk of Early-Onset Colorectal Cancer Precursors Among Women
November 2025 A new study published in JAMA Oncology found that women who eat more ultraprocessed foods (UPFs) such as packaged snacks, sugary drinks, and...
Microplastics in the Gut Linked to Colorectal Cancer-Like Patterns
November 2025 New research from the microONE project (CBmed GmbH, Austria) suggests that microplastics may impact gut health by altering...
